INTRABIOTICS PHARMACEUTICALS INC /DE
EX-10.24
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>6
<FILENAME>j1229_ex10d24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>

<head>
<title>Prepared by MerrillDirect</title>
</head>

<body>

<div>

<p align=right><b><font size=2>Exhibit 10.24</font></b></p>

<p align=center><b><font size=2>FIRST AMENDMENT</font></b></p>

<p align=center><b><font size=2>TO THE AGREEMENT</font></b></p>

<p align=center><b><font size=2>BETWEEN</font></b></p>

<p align=center><b><font size=2>INTRABIOTICS PHARMACEUTICALS,
INC.</font></b></p>

<p align=center><b><font size=2>AND</font></b></p>

<p align=center><b><font size=2>ALBANY MOLECULAR RESEARCH, INC.<page></font></b></p>

<p align=center><b><font size=2>FIRST AMENDMENT<br>
TO THE RESEARCH AND TECHNOLOGY AGREEMENT<br>
BETWEEN<br>
INTRABIOTICS PHARMACEUTICALS, INC.<br>
AND<br>
NEW CHEMICAL ENTITIES, INC.</font></b></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; THIS FIRST AMENDMENT TO THE RESEARCH AND TECHNOLOGY
AGREEMENT</font></b><font size=2> is entered into as of the 13th day of April, 2001, (&#147;Amendment Effective
Date&#148;) by and among </font><b><font size=2>INTRABIOTICS PHARMACEUTICALS, INC.</font></b><font size=2>, a Delaware corporation (&#147;INTRABIOTICS&#148;) and </font><b><font size=2>ALBANY
MOLECULAR RESEARCH</font></b><font size=2>, a Delaware corporation (&#147;AMRI&#148;).</font></p>

<p align=center><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RECITALS</font></b></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHEREAS,</font></b><font size=2> INTRABIOTICS
and New Chemical Entities, Inc. (NCE) entered into a Research and Technology
Agreement dated January 24, 2001 (the &#147;Original Agreement&#148;) for the screening
of NCE&#146;s proprietary natural product libraries by INTRABIOTICS and its
contractors;</font></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHEREAS</font></b><b><font size=2>,</font></b><font size=2> AMRI acquired NCE subsequent to the execution of
the Original Agreement and is the successor in interest to NCE with respect to
the Original Agreement;</font></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHEREAS</font></b><b><font size=2>,</font></b><font size=2> to carry out certain parts of the Research Program,
INTRABIOTICS intends to enter into a Screening Agreement with Cetek Corporation
(&#147;Cetek&#148;) pursuant to which Cetek will utilize Cetek technology to screen the
Screening Libraries licensed by AMRI to INTRABIOTICS; and</font></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHEREAS,</font></b><font size=2> INTRABIOTICS and AMRI desire to amend and clarify
their respective rights under the Agreement to provide, among other things,
that Cetek will own the Cetek Technology.</font></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOW, THEREFORE,</font></b><font size=2> in consideration of the foregoing and the covenants
and promises contained in this Amendment, INTRABIOTICS and AMRI hereby amend
the Agreement as follows:</font></p>

<p align=left><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.</font><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unless
otherwise expressly provided herein, defined terms used in this First Amendment
shall have the same meaning as set forth in the Original Agreement, and all
terms herein shall be incorporated into the Original Agreement.&nbsp; From and after the Amendment Effective Date,
all reference to the &#147;Research and Technology Agreement&#148; in all other documents
delivered in connection with the Research and Technology Agreement shall refer
to the Research and Technology Agreement, as amended hereby.</font></p>

<p align=left><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All
references to &#147;New Chemical Entities&#148; shall be replaced with &#147;Albany Molecular
Research&#148; and all references to &#147;NCE&#148; shall be replaced with &#147;AMRI&#148;.<page>

<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 1.14 shall be amended to read as follows:</font></p>

<dir>
<p align=left><font size=2>1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;AMRI Research Program
Technology&quot; means all information, know-how, trade secrets, inventions and
data that are made during the course of the parties&#146; performance under the
Research Program that are not Exclusive Research Program Technology, Cetek
Technology or Other Technology.</font></p>
</dir>

<p align=left><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.</font><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A new Section 1.33 shall be inserted
as follows:</font></p>

<dir>
<p align=left><font size=2>1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#147;Other Technology&#148; means all information,
know-how, trade secrets, inventions and data that are made or discovered during
the course of the INTRABIOTICS&#146; performance under the Research Program, whether
performed by INTRABIOTICS or a contractor of INTRABIOTICS set forth in Appendix
C other than Cetek, which relate to the screening, isolation or ranking of
compounds that associate with proteins or macromolecular targets, including,
but not limited to any screening assay, the Targets and any data relating
thereto. Other Technology shall not include: the Cetek Technology, the
Screening Libraries, and&nbsp; Structure Technology.</font></p>
</dir>

<dir>
<p align=left><font size=2>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A new Section 1.34 shall be inserted
as follows:</font></p>
</dir>

<dir>
<p align=left><font size=2>1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#147;Cetek Technology&#148; means all know-how,
trade secrets, inventions, data, processes, procedures, devices, methods,
formulas, reagents and protocols and other information, including improvements
thereon, whether or not patentable, now or hereafter owned or controlled by
Cetek or developed or discovered by Cetek in the course of screening the
Screening Libraries, for the screening or isolation or ranking of compounds
that associate with proteins or macromolecular targets, including, but not
limited to, any capillary electrophoresis assay. Cetek Technology shall not
include:&nbsp; (1) the Screening Libraries
and any data relating thereto, (2) the Targets and any data relating thereto,
(3) Screening Data, and (4) the Structure Technology.</font></p>
</dir>

<p align=left><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.</font><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 6.1 shall be amended to read
as follows:</font></p>

<dir>
<p align=left><font size=2>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inventorship of any inventions arising
out of the Research Program shall be determined according to U.S. patent
law.&nbsp; AMRI shall own all right, title
and interest in the AMRI Research Program Patents, Exclusive Research Program
Patents, Exclusive Research Program Technology, AMRI Research Program
Technology and Structure Technology in each case, regardless of
inventorship.&nbsp; INTRABIOTICS shall own
all Other Technology and all intellectual property rights related thereto and
all Screening Data.&nbsp; Cetek shall own all
Cetek Technology.</font></p>
</dir>

<dir>
<p align=left><font size=2>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 6.2 shall be amended to read
as follows:</font></p>
</dir>

<dir>
<p align=left><font size=2>6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each party shall continue to own all
intellectual property owned by such party prior to the Effective Date.&nbsp; Such intellectual property shall be referred
to herein as such party&#146;s &#147;Background Technology&#148;.</font></p>
</dir>

<page>


<dir>
<p align=left><br>
<font size=2>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A new
Section 6.9 shall be added as follows:</font></p>
</dir>

<dir>
<p align=left><font size=2>6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The parties acknowledge and agree that
each of them is conducting research and development of its respective
Background Technology on an ongoing basis.&nbsp;
In the event that any resulting improvements to such Background
Technology or other resulting inventions or developments include know-how,
trade secrets, inventions, data, processes, procedures, devices, methods,
formulas, reagents, protocols and other information which (i) are already known
or in a party&#146;s possession, other than under an obligation of confidentiality
to the other party, or (ii) are developed independently by an employee of a
party without benefit of the other party&#146;s confidential information or
technology, or (iii) become generally available to the public other than as a
result of a disclosure by a party or such party&#146;s directors, officers,
employees, agents or advisors, or (iv) become available to a party on a
non-confidential basis from a source other than the other party or its
advisors, provided that such source is not known by the receiving party to be
bound by a confidentiality agreement with or other obligation of secrecy to the
other party or another party (&#147;Intellectual Property&#148;), ownership of such
Intellectual Property shall be determined according to applicable law.&nbsp; As used in this Section 6.9 the term &#147;party&#148;
shall mean a party to this agreement and its sublicensees.</font></p>
</dir>

<p align=left><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A
new Section 1.35 shall be added as follows:</font></p>

<dir>
<p align=left><font size=2>1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#147;Structure Technology&#148; shall mean any
inventions or discoveries made by Cetek in the course of screening the
Screening Libraries which relate specifically to the making, using or
composition of a particular Active Structure, Target or Sample and have little
or no utility for natural product extracts and protein or macromolecular
targets generally.</font></p>
</dir>

<p><font size=2>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 2.6 shall be amended to read as
follows:</font></p>

<dir><dir>
<p align=left><font size=2>In the event that
INTRABIOTICS desires to isolate and/or identify the chemical structure of a
compound within a Screening Library, INTRABIOTICS agrees, except to the extent
permitted under Section 2.5, that it will not attempt to perform such
separation and/or identification itself, and will not request any person or
entity other than AMRI to perform such separation or identification.&nbsp; In the event that INTRABIOTICS is unable to
transfer or cause to be transferred to AMRI a bio-assay to guide fractionation
and dereplication experiments, INTRABIOTICS may request that Cetek perform
fractionation to separate or identify the active fractions and Cetek may
perform such fractionation only as permitted under this Section 2.6.&nbsp; Upon the request of the RMC, Cetek will
supply such fractionated material to AMRI for dereplication studies.&nbsp; Using the fractionated material, Cetek may
perform studies to evaluate reversibility of binding.</font></p>
</dir></dir>

<page>


<dir>
<p align=left><br>
<font size=2>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 1.30 shall be amended to read as follows:</font></p>
</dir>

<dir>
<p align=left><font size=2>1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#147;Target&#148; means INTRABIOTICS&#146; targets of
interest as listed in Appendix B, as may be amended from time to time by
INTRABIOTICS during the Research Program.&nbsp;
A Target may be proprietary to third parties other than those
consultants of INTRABIOTICS listed in Appendix C, or in the public domain.</font></p>
</dir>

<dir>
<p align=left><font size=2>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Except as otherwise amended herein, the
Agreement shall remain in full force and effect.</font></p>
</dir>

<p align=left><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This First Amendment may be executed in
counterparts and by facsimile.</font></p>

<p align=left><font size=2>This
Amendment shall be effective as of the date first written above.</font></p>

<p align=left><b><font size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IN WITNESS WHEREOF</font></b><b><font size=2>,</font></b><font size=2> the parties hereto have duly executed this
Amendment.</font></p>

<table border=0 cellspacing=0 cellpadding=0 width="100%">
 <tr>
  <td  align=left width="50%" colspan=2 valign=top><b><font size=2>INTRABIOTICS PHARMACEUTICALS, INC.</font></b></td>
  <td  align=left width="50%" colspan=2 valign=top><b><font size=2>ALBANY MOLECULAR RESEARCH, INC.</font></b></td>
 </tr>
 <tr>
  <td  align=left width="5%" valign=top>&nbsp;</td>
  <td  align=left width="44%" valign=top>&nbsp;</td>
  <td  align=left width="6%" valign=top>&nbsp;</td>
  <td  align=left width="43%" valign=top>&nbsp;</td>
 </tr>
 <tr>
  <td  align=left width="5%" valign=top><font size=2>By:</font></td>
  <td  align=left width="44%" valign=top><font size=2>/s/&nbsp;
  Kenneth J. Kelley</font></td>
  <td  align=left width="6%" valign=top><font size=2>By:</font></td>
  <td  align=left width="43%" valign=top><font size=2>/s/&nbsp;
  Donald E. Kuhla</font></td>
 </tr>
 <tr>
  <td  align=left width="5%" valign=top>&nbsp;</td>
  <td  align=left width="44%" valign=top>
<hr size=1 width="75%" noshade color=black align=left></td>
  <td  align=left width="6%" valign=top>&nbsp;</td>
  <td  align=left width="43%" valign=top>
<hr size=1 width="75%" noshade color=black align=left></td>
 </tr>
 <tr>
  <td  align=left width="5%" valign=top><font size=2>Title:</font></td>
  <td  align=left width="44%" valign=top><font size=2>President and Chief Executive Officer</font></td>
  <td  align=left width="6%" valign=top><font size=2>Title:</font></td>
  <td  align=left width="43%" valign=top><font size=2>President and Chief Operating Officer</font></td>
 </tr>
 <tr>
  <td  align=left width="5%" valign=top>&nbsp;</td>
  <td  align=left width="44%" valign=top>
<hr size=1 width="75%" noshade color=black align=left></td>
  <td  align=left width="6%" valign=top>&nbsp;</td>
  <td  align=left width="43%" valign=top>
<hr size=1 width="75%" noshade color=black align=left></td>
 </tr>
</table>

<p align=center><font size=2>&nbsp;</font></p>

<p><font size=3 face=Times>&nbsp;</font></p>

<p><font size=2 face=Times>&nbsp;</font></p>

</div>

</body>

</html>

</TEXT>
</DOCUMENT>
